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Abstract
Background: The rheumatoid arthritis (RA) shared epitope (SE), a major risk factor for severe disease, is a five amino acid
motif in the third allelic hypervariable region of the HLA-DRb chain. The molecular mechanisms by which the SE affects
susceptibility to – and severity of - RA are unknown. We have recently demonstrated that the SE acts as a ligand that
interacts with cell surface calreticulin (CRT) and activates innate immune signaling. In order to better understand the
molecular basis of SE-RA association, here we have undertaken to map the SE binding site on CRT.
Principal Findings: Surface plasmon resonance (SPR) experiments with domain deletion mutants suggested that the SE
binding site is located in the P-domain of CRT. The role of this domain as a SE-binding region was further confirmed by a
sulfosuccinimidyl-2-[6-(biotinamido)-2-(p-azido-benzamido) hexanoamido] ethyl-1,3-dithiopropionate (sulfo-SBED) photo-
active cross-linking method. In silico analysis of docking interactions between a conformationally intact SE ligand and the
CRT P-domain predicted the region within amino acid residues 217–224 as a potential SE binding site. Site-directed
mutagenesis demonstrated involvement of residues Glu
217 and Glu
223 - and to a lesser extent residue Asp
220 - in cell-free
SPR-based binding and signal transduction assays.
Significance: We have characterized here the molecular basis of a novel ligand-receptor interaction between the SE and
CRT. The interaction represents a structurally and functionally well-defined example of cross talk between the adaptive and
innate immune systems that could advance our understanding of the pathogenesis of autoimmunity.
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Introduction
The ‘‘shared epitope’’ (SE) is a five amino acid sequence motif
in positions 70–74 of HLA-DRb chains encoded by HLA-DRB1
alleles that are strongly associated with susceptibility to severe
rheumatoid arthritis (RA). The mechanism underlying SE-RA
association is unclear. Based on the known role of MHC class II
molecules in presentation of antigenic peptides to helper T cells, it
has been hypothesized over the past two decades that RA-SE
association is due to presentation of arthritogenic self or foreign
peptides [1,2]. However, this theory is difficult to reconcile with
lack of conclusive evidence to support antigen-specific responses as
the primary event in RA, the promiscuous association of the SE
with other human diseases and various autoimmunity models in
different species, plus the unexplained SE gene-dose effect on
disease severity and penetrance (reviewed in [3]).
Based on our recent data [4,5,6], we have proposed an
alternative hypothesis, postulating that the SE, analogous to
certain domains of class I MHC-molecules [7,8], acts as an innate
immune system ligand. We have demonstrated that the SE acts as
a signaling ligand in its native conformation within cell surface-
expressed HLA-DR molecules, as well as a cell-free HLA-DR
tetrameric molecule. The activity could also be observed when the
ligand was genetically engineered into non-HLA recombinant
proteins, or as a short synthetic peptide. In all these configurations,
the SE activated robust production of nitric oxide (NO) and
reactive oxygen species (ROS) in other cells [4,5,6].
In previous studies [6] we have shown that SE-activated
signaling depends on cell surface calreticulin (CRT). The affinity
of SE-CRT interaction was calculated to be at a low-mM range,
similar to many other receptor-ligand interactions in the immune
system. CRT is critical for SE-triggered signaling, as anti-CRT
antibodies and small interfering RNA oligonucleotides blocked
SE-activated signaling and murine embryonic fibroblasts (MEF)
from crt
2/2 mice failed to transduce SE-activated signals.
However, when soluble CRT was exogenously added to crt
2/2
cells, it attached to the cell surface and restored signaling
responsiveness [6]. Thus, SE-activated signaling depends on
binding to cell surface CRT, which plays a critical role in signal
transduction.
CRT is an endoplasmic reticulum chaperone, which also
functions as a co-receptor when expressed on the cell surface [9]. It
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11703has long been known to function as an innate immune system
receptor. For example, CRT has been implicated as a receptor for
C1q, mannose binding lectin and members of the collectin family
[10,11]). Due to its critical importance for elimination of apoptotic
cells [12], CRT is believed to play a pivotal role in the junction
between tolerance and autoimmunity [13]. Aberrant activation of
the CRT-mediated pathway can lead to autoimmunity, as
exemplified by conditions that involve defective CRT-mediated
clearance of apoptotic cells [14]. CRT has been previously
hypothesized to play a role in autoimmune human diseases,
including RA [15]. Thus, our findings that CRT serves as the
signal transduction receptor for SE, a major factor in RA disease
susceptibility and severity, could provide important new insights
into the role of CRT in autoimmunity. To gain better
understanding of SE-CRT interaction, here we have undertaken
to map the SE binding site on CRT.
Results
Identification of the SE-binding CRT domain
The primary sequence of CRT suggests that similar to calnexin
it has three domains [16]. Because the tri-dimensional structure of
CRT has not been fully resolved, it is a common practice in the
literature to model it based on the known crystal structure of
calnexin [17]. According to this model (Fig. 1A) the amino-
terminal segment (N-domain) has a globular b-sheet structure.
This domain is followed by a proline-rich sequence, called the
P-domain that folds into a long hairpin-like structure with two
pairs of short anti-parallel b-sheet sequences. The third region of
CRT, called the C-domain, forms, together with the N-domain, a
globular ‘‘head’’ to the molecule.
To determine to which of these three domains the SE binds, we
first used domain deletion mutants that code truncated segments
of CRT (Fig. 1B). The recombinant products of these mutants
were immobilized on a CM5 biosensor chip and their binding to
SE-expressing 15mer peptides was assayed as previously described
[6]. As can be seen in the Figures 1C and 1D, consistent with our
previous report [6], SE-expressing peptides 65-79*0401 and 65-
79*0404 both interacted with the intact CRT molecule.
Truncated proteins containing single domains (N, P or C-domains)
failed to bind the SE. However, when truncated proteins
containing the N-domain plus P-domain, or P-domain plus C-
domain were tested, near-normal binding interactions could be
seen. This pattern indirectly implicates the P-domain and suggests
that a conformation-dependent binding site is involved.
To more directly identify the binding domain, we have used
a photoactive cross-linking approach with sulfosuccinimidyl-2-
[6-(biotinamido)-2-(p-azido-benzamido) hexanoamido] ethyl-1,3-
dithiopropionate (sulfo-SBED) [18]. This cross-linker has 4
functional groups: a NHS-ester group, a UV-activatable aryl azide
group, a cleavable disulfide bond, and a biotin group (Figure 2A).
The NHS-ester group was chemically attached to the N-terminal
amine group of SE-positive peptide 65-79*0404 and the compound
was allowed to interact with CRT. Following UV cross-linking,
Figure 1. Interaction between the SE and domain-deleted CRT. A. A theoretical 3D structure of CRT. Rabbit CRT (Accession No. AAB20096)
was computationally modeled based on the known crystal structure of Calnexin (PDB ID: 1JHN), using Modeler 9v7 software (School of Pharmacy,
UCSF). CRT N-domain is shown in green, P-domain is in cyan and C-domain is shown in orange. B. Schematic representation of rabbit CRT domain-
deletion mutants. C,D. SPR-based interactions between the SE ligand and CRT domain-deletion mutants. WT CRT or its domain-deletion mutants
were immobilized on a CM5 biosensor chip surface and the SE peptidic ligands 65-79*0401 (C) or 65-79*0404 (D) were run in the analyte.
doi:10.1371/journal.pone.0011703.g001
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CRT protein digest was captured by an avidin column, and the
affinity-purified biotinylated fragments were analyzed by mass
spectrometry (MS). A representative experiment, one of two
repetitions, is shown in Fig. 2. Four major peaks were identified
(Fig. 2B). Of these, peaks 1895 and 1582 were found to correspond
to contaminating non-CRT peptides (avidin and the SE peptides,
respectively, data not shown). However, peaks 1838 (Fig. 2C) and
2047.1 (Fig. 2D) were found to correspond, respectively, to the 262–
275 and 196–211 regions in the CRT P-domain. It is worth noting
that despite a 51 amino-acid distance between the two regions,
NMR data [19] indicate that they are spatially adjacent – on
opposite sides of the two antiparallel arms of the P-domain hairpin
structure (Fig. 2E). Given the size of the sulfo-SBED compound
(Fig. 2A), when taken together, these findings strongly suggest that
the SE binding site is located in the CRT P-domain, within ,30 A ˚
from regions 262–275 and 196–211.
Computer simulation of SE-CRT interaction
In order to identify candidate SE binding sites on CRT P-
domain, we have used the BioMedCAChe 6.1 docking software.
To this end, the third allelic hypervariable region (aa 65–79) of the
HLA-DR b chain, including the SE ligand region (aa 70–74) was
modeled in its a helical conformation as predicted by HLA-DR1
[20] and HLA-DR4 [21] crystal structure data. The P-domain was
maintained in its tri-dimensional conformation as previously
predicted by NMR analysis [19]. The conformationally-rigid SE
ligand and the CRT P-domain (PDB ID: 1HHN) were docked
using the BioMedCAChe Augmented MM3 software. As shown in
Table 1, four docking models with significant levels of docking
energy were identified. Intriguingly, all four models predicted the
region 217–224 as the binding site.
The two most significant docking models aredepicted graphically
in Figure 3. As can be seen, in model A (the most significant one,
with docking score of 2232 kcal/mole), CRT residues Glu
217 and
Figure 2. Photoactive cross-linking studies. A. Structural formula of Sulfo-SBED. B. MS analysis of trypsinized sulfo-SBED-labeled CRT fragments.
C. MS/MS data of peak 2047.1 (marked as ‘‘C’’ in Fig. 2B) identifying CRT segment 196-KIKDPDASKPEDWDER-211. D. MS/MS data of peak 1838
(marked as ‘‘D’’ in Fig. 2B) identifying CRT segment 262-GEWKPRQIDNPDYK-275. E. Spatial proximity of peaks 2047.1 (red) and 1838 (blue), as
predicted by NMR-based tri-dimensional analysis of the CRT P-domain [19].
doi:10.1371/journal.pone.0011703.g002
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220 interact with SE residue Gln
70, while CRT residues Glu
223
and His
224 interact with SE residue Arg
72. In model B (docking
score of 2170 kcal/mole), CRT residue Glu
223 is in close proximity
to SE residues Lys
71 and Gln
70, while CRT Asp
220 is in close
proximity to SE residue Gln
70 and Ala
74.
Site-directed mutational analysis
Based on the docking models mentioned above, we next
performed site-directed mutagenesis in residues predicted to
interact with the SE. The resultant point-mutated recombinant
proteins were analyzed by circular dichroism (CD) spectroscopy
and showed only minor, insignificant alterations in the secondary
structure (Supplemental Figure S1).
To determine the effect of individual substitutions on CRT-SE
interaction, we first used a SPR assay. Wild-type (WT) or mutant
CRT proteins were immobilized on a biosensor chip at about 500
RU using a standard primary amine coupling method. SE peptidic
ligands 65-79*0401 or 65-79*0404 were run as analyte. The results
are summarized in Table 2. As can be seen, the CRT E217A and
E223A mutants, but not mutants D220A, H224A, Y254A or
N279A, showed significantly lower binding of both SE ligands.
Notwithstanding the seemingly modest variations in SE-binding
potency among the different CRT species, these differences were
reproducible, statistically significant and, more importantly, corre-
lated well with signaling potencies, as discussed below.
We [6] and others [22,23] have previously demonstrated that
soluble CRT can attach to the cell surface and restore CRT
receptor-mediated signaling in CRT-negative cells. Accordingly,
to determine the effect of CRT point mutations on signal
transduction, soluble WT or mutant CRT proteins were added
to crt
2/2 cell line K42 [24]. There was no difference in cell surface
binding capacity between WT CRT and its mutants (data not
shown). As can be seen in Fig. 4A, CRT mutant E217A failed to
transduce SE-activated ROS signaling and mutant E223A
transduced a significantly reduced signals compared to the WT
protein. No significant signaling inhibition was caused by either
the D220A or Y282A mutations. Representative time-course ROS
production curves with WT CRT and mutant E217A are shown
in Fig. 4B. As can be seen, the E217A mutation produced
complete inhibition of SE-activated ROS production. Consistent
with our previous data showing close correspondence between NO
and ROS signaling [4,5,6], Figures 4C and 4D demonstrate that
the inhibitory effect of mutated residues 217 and 223 affected both
NO and ROS signaling. Importantly, Figure 4 demonstrates that
the inhibitory effect on SE-activated signaling by mutated residues
217 and 223 could be seen when the SE was expressed in its
natural tri-dimensional conformation in the form of a tetramer
Table 1. Docking models: Interactions between SE and CRT
residues.
Residues 70–74 (DRB1*0401)
Model
Docking score
(kcal/mole) Gln
70 Lys
71 Arg
72 Ala
73 Ala
74
A 2232 Glu
217 Asp
220 Asp
220
Asp
220 Glu
223
His
224
B 2170 Glu
223 Glu
223 His
224 Asp
220
His
224
C 2166 Glu
223 Asp
220
His
224
D 292 Asp
220 Asp
220
Glu
223
doi:10.1371/journal.pone.0011703.t001
Figure 3. SE-CRT docking models. Graphic representation of the two most significant docking models shown in Table 1: Model A (left) and Model
B (right). Closer views of the interactions between CRT (black font) and SE (cyan font) residues are shown in the lower panels.
doi:10.1371/journal.pone.0011703.g003
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conformation in Hepatitis B core (HBc) particles (Figures 4C and
4D). Consistent with our prior studies [6], no measurable
differences in cell survival were observed in the presence or
absence of WT CRT or its mutants (not shown). Although the data
clearly implicate residues Glu
217 and Glu
223, it should be pointed
out that Fig 4C suggests that, albeit weakly, residue Asp
220 may be
involved as well. Taken together, our findings indicate that SE-
activated signaling maps to the 217–223 region of the CRT P-
domain and depends primarily on Glu
217 and Glu
223 and, to a
lesser extent, on Asp
220.
Discussion
We have previously demonstrated that the SE interacts with cell
surface CRT and activates innate immune signaling [4,5,6]. To
better characterize this interaction, here we determined the SE
binding site on CRT. By using a combination of SPR-based
binding studies, photoactive cross-linking methods, an in silico
docking simulation and mutational analysis, we have mapped the
SE binding site to the 217–223 region of CRT P-domain and
identified residues Glu
217 and Glu
223 as key players.
The mature CRT protein contains three structurally and
functionally distinct domains. The 180 N-terminal amino acid
residues and the 115 C-terminal residues form the N-domain and
a C-domain, respectively. Based on the known crystal structure of
a homologous protein calnexin, these domains are predicted to
fold into a composite globular domain. The intervening sequence
(residues 181-284), is proline-rich and is therefore called the P-
domain. This domain has been shown by NMR studies to form an
arm-like hairpin structure, stabilized by two antiparallel b-sheets
Figure 4. Identification of CRT residues that are critical for SE-activated signaling. A. K42 crt
2/2 MEF cells were pre-incubated overnight
with 1 mg/ml of WT CRT or its mutants. Then, the SE-expressing HLA-DR tetramer T-DRB1*0401 (24 mg/ml) was added and ROS production rates were
measured as fluorescent units per min (FU/minute). B. Representative time-course curves of ROS production in response to T-DRB1*0401 stimulation
in K42 cells pre-incubated with either WT CRT (g) or CRT-E217A mutant (N). C. K42 crt
2/2 MEF cells were pre-incubated overnight with 1 mg/ml of WT
CRT or its point mutants. Then, the SE-expressing ligand HBc*0401 (20 mg/ml) was added and ROS production was measured as in A. D. K42 crt
2/2
MEF cells were pre-incubated overnight with 1 mg/ml of WT CRT or its point mutants. Then, HBc*0401 was added and NO production rates were
measured. Data are shown as incremental mean 6 SEM values, above the levels obtained in the absence of the receptor and/or the ligand, as in
previous studies [4]. *, p,0.05 compared to WT CRT.
doi:10.1371/journal.pone.0011703.g004
Table 2. SPR interactions between SE ligands and WT or
mutant CRT.
Ligand (SE)
65-79*0401 65-79*0404
Receptor
(CRT) RU % decrease RU % decrease
WT 71.265.0 (13) 127.5610.2 (8)
E217A 50.9±1.5
{ (2) 28.662.0 105.7±4.9
{ (2) 17.1±3.8
D220A 70.166.4 (6) 1.669.0 119.8613.0 (4) 6.0610.2
E223A 56.7±2.9
{ (3) 20.364.0 84.6±14.1
{ (2) 33.667.9
H224A 68.269.8 (3) 4.1613.7 128.4 –
Y254A 66.5 – 112.7624.0 (2) –
N279A 106.1 – 144.9620.3 (2) –
Values are shown as mean 6 SEM. Significantly lower interactions are shown in
bold.
{, p,0.05;
{, p,0.005. The figures in parentheses represent the number of
replicates.
doi:10.1371/journal.pone.0011703.t002
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prior studies have demonstrated that CRT tertiary conformation is
critically important for its biologic activity [25].
The use of photoactive cross-linkers, followed by identification of
cross-linked regions by MS analysis has proven useful in complex
interactions, especially where tertiary conformational factors play a
role [18,26,27]. Using that method, we identified two P-domain
sequences located, respectively, in positions 196–211 and 262–275
of the CRT P-domain. It is worth mentioning that despite a 51
aminoacidresiduesgapintheirprimarysequence,the196–211and
262–275 regions are spatially adjacent, on two anti-parallel segment
of the P-domain hairpin. Moreover, these two regions are both
within the reach of the cross-linking sulfo-SBED compound, 27.9 A ˚
and 23.1 A ˚, respectively, from the SE actual binding site [19].
Our data with HLA-DR tetramers and HBc particles attest to
the significance of the findings, since these physiologically-folded
SE-expressing ligands closely mimic the natural conformation of
the epitope. It should be mentioned that tetramers consist of four
identical units of the HLA-DR molecule, each folded in its native
tertiary conformation. Likewise, SE-expressing HBc particles have
been engineered to allow the SE to be expressed outside of the
HLA-DR context in its native a helical conformation [4].
Therefore, the significance of the point-mutant studies shown
here is two-fold: First, they demonstrate high consistency between
all the different mapping-approaches and, second, by using
conformationally-intact reagents, these studies attest to the
physiologic relevance of the data. Both SPR binding assay and
signaling assay confirm that CRT Glu
217 and Glu
223 play critical
role in binding the SE. However, we cannot rule out the possibility
that other residues on other CRT domains might be involved in
the binding as well. Because crystal structure data on the whole
CRT molecule is unavailable, our computer docking model could
only focus on the CRT P-domain.
The binding site identified here has several unique character-
istics. Most of the previously reported interactions between CRT
and various other proteins were found to involve its C- or N-
domains, whereas little is known about the role the P-domain.
Three notable exceptions in which a P-domain binding site has
been implicated are ERp57 [28,29], C1q [30,31] and the 4-
aminobutyrate type A receptor associated protein (GABARAP)
[17,32].
Using a site-directed mutagenesis approach, Martin et al [29]
have mapped the ERp57 binding site to tip of the P-domain
(residues Glu
239, Asp
241, Glu
243 and Trp
244). That binding site is
different from the one reported here. Additionally, while CRT-
ERp57 interaction takes place inside cells, the interaction reported
here occurs on the cell surface. Cell surface CRT has been long
known as an innate immune system receptor that binds and
transduces C1q signals [30,31]. The binding site of the collagen-
like segment of C1q was assigned to an ‘‘S-domain’’, a CRT
fragment (residues 160–283), which spans both the N- and P-
domains [33]. The precise site in this fragment that binds C1q has
not been mapped to date and therefore its relevance to the SE
binding site (residues 217–223) cannot be determined. The third
known P-domain-binding ligand is GABARAP, a nervous system
adaptor protein that plays a role in intracellular vesicle trafficking.
Thielmann et al [17] have demonstrated that CRT residue Trp
183
plays a critical role in GABARAP-CRT interaction. No site
specific mutagenesis of the CRT protein was attempted in those
studies. Given the location of Trp
183 near the junction between the
N-domain and P-domain, the study could not rule out participa-
tion of the N-domain in stabilizing the interaction between
GABARAP and CRT [17].
It is worth mentioning that, different from GABARAP that
interacts with CRT intracellularly, the SE represents an
extracellular ligand that activates signaling through its interaction
with cell surface CRT. Thus, the distance between Trp
183 and the
SE-binding site, the dissimilarity in the biologic effect of the two
pathways and their distinct compartmentalization, all suggest that
the SE and GABARAP binding sites are neither structurally nor
biologically related. Thus, the SE binding site reported here is
unique, both topologically and functionally.
Based on the critical role of CRT residues Glu
217 and Glu
223
shown here, on the one hand and the previously determined
functional role of individual SE residues on the other, Figure 5
depicts a proposed model of CRT-SE interaction. According to
this model - and consistent with docking Model A discussed
above -, CRT Glu
217 interacts with SE Gln
70, while CRT Glu
223
interacts with SE Arg
72. This model is supported by several
considerations: 1. Model A has been assigned the most significant
docking score (2232 kcal/mole); 2. Different from the other
docking models considered here, it implicates Glu
217, a residue
that shows the most significant impact on both binding and
signaling; 3. It involves Gln
70 on the SE side, a residue that has
been previously shown to play a critical role in RA pathogenesis
[34,35]; 4. It involves the SE Arg
72, a residue that is common to all
the SE variants (QKRAA, QRRAA and RRRAA). 5. This model
allows for engagement of both the CRT P-domain and the groove
peptide without spatial interference (Fig. 5). In order to examine
this model, we are presently gearing towards experiments with
Figure 5. Proposed CRT-SE interaction model. A. A SE-positive HLA-DR4 molecule (PDB ID: 2SEB) interacting with the SE-binding site in the CRT
P-domain. The HLA-DRa chain is shown in green, HLA-DRb chain is in yellow, the SE is in cyan, CRT P-domain is in purple, and the groove peptide is
shown in orange. B. A closer view of the interactions between CRT Glu
217 and SE Gln
70 and between CRT Glu
223 and SE Arg
72.
doi:10.1371/journal.pone.0011703.g005
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(residues 70–74). It should be mentioned, however that while point
mutation analyses on both sides will help clarifying the spatial
confines of SE-CRT interaction, more definitive data might be
obtained from co-crystallization studies. Unfortunately, such
studies may be technically challenging, given that the crystal
structure of CRT has not been resolved to this date.
In summary, we have characterized here a biologically
consequential interaction site between the SE, a physiologically-
folded novel extracellular ligand, and the innate immunity
receptor CRT. The interaction represents a structurally and
functionally well-defined example of cross talk between the
adaptive and innate immune systems. In order to better
understand the role of this interaction in disease pathogenesis,
we are presently determining the functional consequences of SE-
CRT activated pathway in the immune system. These studies
could shed new light on the function of the SE and help to advance
our understanding of its role in RA.
Materials and Methods
Cells and reagents
The mouse embryonic fibroblast (MEF) line K42, isolated from
crt
2/2 mice, has been previously described [24]. pBAD-rCRT-
His6, pGEX-rCRT, and its domain deletions pGEX-rCRT-N(1-
182), pGEX-rCRT-P(139-273), pGEX-rCRT-C(270-401), pGEX-
rCRT-N+P(1-290), and pGEX-rCRT-P+C(139-401) plasmids were
prepared as described [36,37]. Ni-NTA Superflow resin and other
molecular biology reagents were purchased from QIAGEN
(Valencia, CA). Diaminofluorescein Diacetate (DAF-2 DA) was
purchased from EMD-Calbiochem (Gibbstown, NJ), and 5-(and-6)-
chloromethyl-29,7 9 dichlorodihydrofluorescein (CM-H2DCFDA)
was purchased from Invitrogen (Carlsbad, CA). SE ligands
expressed as either 15mer synthetic peptides (65-79*0401 or 65-
79*0404), engineered into hepatitis B core particles (HBc*0401) or
in the form of HLA-DR tetramers (T-DRB1*0401) were prepared
as previously described [4,5,6]. All other chemicals were from
Sigma (St. Louis, MO). Mouse crt cDNA was generated from brain
tissue of DBA/1 mice using standard techniques. DNA sequence
was confirmed with the GenBank Database (Accession no.
AK075605).
Surface plasmon resonance (SPR)
SPR experiments were performed with a BIAcore2000
instrument (GE Healthcare, Piscataway, NJ) as we described [6].
All assays were performed at 25uC in a binding buffer containing
10 mM HEPES, pH 7.4, 50 mM KCl, 0.5 mM CaCl2, 100 mM
ZnCl2, and 0.005% surfactant P-20. The analyte was injected at a
flow rate of 10 ml/min.
Photoactive cross-linking studies
The sulfosuccinimidyl-2-[6-(biotinamido)-2-(p-azido-benzamido)
hexanoamido] ethyl-1,3-dithiopropionate (Sulfo-SBED) method
was used according to the manufacture’s (Thermo Scientific,
Waltham, MA) instructions. Briefly, the 15mer peptide 65-
79*0404 was labeled with Sulfo-SBED in an equal molar ratio,
using the ProFound
TM Sulfo-SBED Biotin Label Transfer Kit
(Thermo Scientific). Extra Sulfo-SBED was removed by gel
filtration. Peptide-protein interaction was performed by incubating
Sulfo-SBED-labeled 65-79*0404 with purified rabbit CRT in the
dark at room temperature for 1 hr. Cross linking was achieved by
UV irradiation using a Philips UV lamp (360 nm, 40 W, 3 D
system PCA) for 15 minutes on ice at a distance of 5 cm. After
cleaving the disulfide bond by DTT, the Sulfo-SBED-cross-linked
CRT was trypsinized overnight at 37uC. Biotin-labeled peptide
fragments were then isolated by a monomeric avidin column.
Mass spectrometric identification of biotin-labeled peptide
fragments was performed in the University of Michigan Proteome
Mapping Core. Briefly, 5 mlo fa-cyano-4-hydroxycinnaminic acid
(5 mg/ml in 50% acetonitrile, 0.1% TFA, 2 mM ammonium
citrate) matrix was added to the 30 ml of concentrated biotinylated
peptides. The samples were brought to dryness and 5 mlo f5 0 %
acetonitrile/0.1% TFA were added back into the well. 0.5 mlo ft h i s
solution was hand-spotted on a 192-well target plate and allowed to
dry. MALDI TOF/TOF mass spectra were obtained using an
AppliedBiosystems 4800 ProteomicsAnalyzer.Peptide masseswere
acquired for the range of 800–3500 Da. Mass spectra were summed
from 2,000 laser shots from an Nd-YAG laser operating at 355 nm
and 200 Hz. Three trypsin autolysis peaks were used for internal
calibration. MS/MS spectra were acquired in MS/MS 2 kV
Positive mode. Spectra were acquired for 6,000 laser shots, or until
5-peptide fragment ions reached a signal-to-noise ratio of 100.
Fragmentation of the peptides was induced by the use of
atmosphere as a collision gas with a pressure of ,6610
27 torr
and collision energy of 2 kV. Database searching was performed
using Applied Biosystems GPS Explorer v. 3.6, with Mascot v. 2.1.
Docking models
The BioMedCAChe 6.1 software (Fujitsu, Sunnyvale, CA) was
used for in silico modeling of the interaction between the SE and
the CRT P-domain. The b-chain third allelic hypervariable
regions (residues 65–79) of HLA-DR1 (PDB ID: 1T5X) and HLA-
DR4 (PDB ID: 2SEB) were used as ligands and the rat CRT P-
domain (PDB ID: 1HHN) was used as the receptor. Both binding
partners were modeled in their rigid conformation, using
augmented MM3 parameters [38]. Docking scores were calculated
using the manufacturer’s software. In all cases, the minimum
potential energy was calculated for the most stable geometry.
Site-directed mutagenesis
CRT site-directed mutants were generated following the
QuikChange protocol (Stratagene La Jolla, CA). The primers
used in this study are listed in supplemental Table S1. Sequences
were verified by the University of Michigan DNA Sequencing
Core. Rabbit and mouse wild-type CRT and site-directed mutants
were constructed in pBAD vector. Wild-type and mutant CRT
plasmids were transformed into GC10 cells for protein expression.
The 66His-tagged protein expression was induced by 0.002% L-
arabinose for 4 hr and the protein was purified using a Ni-NTA
resin, following the manufacturer’s (QIAGEN, Valencia, CA)
protocol. Rabbit CRT domain-deletion mutants were constructed
in a pGEX vector. GST-fusion CRT domain-deletion mutants
were expressed and purified as previously reported [36,39]. The
GST segment was removed by Factor Xa.
Circular dichroism spectroscopy
Proteins were in a 5 mM HEPES (pH 7.4), 100 mM KF, 2 mM
CaCl2 buffer. CD spectra were determined in 1 mm bandpass
quarta cuvettes by far-UV circular dichroism on an Aviv 215
spectropolarimeter (Aviv Associates, Lakewood, NJ). Correspond-
ing baseline levels were obtained with buffer only and subtracted
from the sample spectrum.
Signal transduction assays
To measure NO production, crt
2/2 MEF, 30,000 cells per well,
were seeded in a 96-well plate. Cultures were loaded with 1 mg/ml
of recombinant WT or mutant CRT overnight. Cells were then
Shared Epitope Binding Site
PLoS ONE | www.plosone.org 7 July 2010 | Volume 5 | Issue 7 | e11703labeled by 20 mM DAF-2 DA and stimulated with SE ligands. NO
production rates were determined as we previously described [4].
ROS production was quantified similarly, with the exception that
cells were labeled with 10 mM CM-H2DCFDA as we previously
described [5].
Supporting Information
Figure S1 CD spectra of WT CRT and its mutants. Proteins, in
a 5 mM HEPES (pH 7.4), 100 mM KF, 2 mM CaCl2 buffer were
placed in 1 mm bandpass quarta cuvettes and analyzed by far-UV
circular dichroism on an Aviv 215 spectropolarimeter (Aviv
Associates, Lakewood, NJ). Corresponding baselines were ob-
tained with buffer which were subtracted from the sample
spectrum. No statistically significant conformational differences
between WT CRT and its mutants were found.
Found at: doi:10.1371/journal.pone.0011703.s001 (0.26 MB
DOC)
Table S1 Primers for rabbit and mouse CRT site-directed
mutants.
Found at: doi:10.1371/journal.pone.0011703.s002 (0.06 MB
DOC)
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